Boston, MA 的 胃癌 臨床試驗
32 項針對 胃癌 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
招募中1 期
- Massachusetts General Hospital, Boston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
招募中3 期
- Dana Farber Cancer Institute, Boston
IKS014 in Advanced Solid Tumors That Express HER2
招募中1 期
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Tufts Medical Center, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
招募中3 期
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
招募中
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
招募中3 期
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
招募中2 期
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
招募中1 期
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital Cancer Center, Boston
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
招募中3 期
- Tufts Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital - Dana Farber, Boston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- 還有 2 項
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
招募中2 期
- I-Mab Site 1002, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
招募中1 期
- Mass General Hospital, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
招募中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
招募中歡迎健康志工
- Dana Farber Cancer Institute, Boston
其他城市的 胃癌 試驗
- Houston, TX42 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Baldwin Park, CA22 項研究
- Los Angeles, CA22 項研究
- Arlington, VA20 項研究
- Dallas, TX19 項研究
- San Antonio, TX19 項研究
- St. Louis, MO18 項研究
- Grand Rapids, MI18 項研究
- Chicago, IL16 項研究
- Washington, DC16 項研究
Boston 的其他研究
- 乳癌112 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）85 項研究
- 轉移性癌症63 項研究
- 大腸直腸癌63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。